Has Rajesh Parekh received payments from drug or device companies?

Yes. Drug and device makers reported $2,885 in general payments to Rajesh Parekh across 177 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rajesh Parekh did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rajesh Parekh come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rajesh Parekh

Psychiatry · Norwich, CTNPI 1710045992

Payments from drug & device makers

$2,885in general payments, 2019–2025

Across 177 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$942
Neurocrine Biosciences, Inc.$522
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$499
Johnson & Johnson$300
E.r. Squibb & Sons, L.L.C.$119
Indivior Inc.$95
plus $408 from 6 others

What the payments were for

Food & beverage$2,80897%
Education$773%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	68	$942
Neurocrine Biosciences, Inc.	40	$522
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	36	$499
Johnson & Johnson	3	$300
E.r. Squibb & Sons, L.L.C.	4	$119
Indivior Inc.	4	$95
Alkermes, Inc.	5	$95
Biodelivery Sciences International, Inc.	3	$91
Sunovion Pharmaceuticals Inc.	6	$73
Otsuka America Pharmaceutical, Inc.	4	$59
Vanda Pharmaceuticals Inc.	2	$58
Corium, LLC	2	$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SPRAVATO$227
CAPLYTA$127

How this compares

$2,885 in reported general payments places this provider in the 85th percentile of 644 psychiatry providers in Connecticut.

See all psychiatry providers in Connecticut →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
AustedoDeutetrabenazine	14	$194,319
SpravatoEsketamine Hcl	153	$185,848
IngrezzaValbenazine Tosylate	16	$136,919
VraylarCariprazine Hcl	70	$95,737
CaplytaLumateperone Tosylate	49	$74,843
LybalviOlanzapine/Samidorphan Malate	23	$36,346
LatudaLurasidone Hcl	15	$22,696
TrintellixVortioxetine Hydrobromide	40	$20,030
VivitrolNaltrexone Microspheres	11	$18,463
Aripiprazole	192	$17,917
Paliperidone ErPaliperidone	14	$17,726
ViibrydVilazodone Hcl	15	$7,825
Desvenlafaxine Succinate ErDesvenlafaxine Succinate	85	$6,640
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	51	$5,814
VyvanseLisdexamfetamine Dimesylate	12	$4,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Johnson & JohnsonSpravato	$300	$185,848153 claims
Neurocrine Biosciences, Inc.Ingrezza	$522	$136,91916 claims
AbbVieVraylar, Viibryd	$942	$103,56285 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta	$499	$74,84349 claims
Alkermes, Inc.Lybalvi, Vivitrol	$95	$54,80934 claims
Sunovion Pharmaceuticals Inc.Latuda	$73	$22,69615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 644 psychiatry providers in Connecticut.

Other psychiatry in Norwich

Mahmoud OkashaNorwich$1.4M
Kelly JaziriNorwich$21K
Walid JaziriNorwich$17K
Vladimir CoricNew Haven$133.7M
Christopher VandyckNew Haven$20.8M
Bart SloanNorwalk$6.8M
Adam MeccaNew Haven$5.1M
David MatuskeyFarmington$3M
Donald AmmermanDanbury$1.5M
Gerard SanacoraNew Haven$1.3M

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →